Quantcast

Latest Non-alcoholic fatty liver disease Stories

2010-04-16 13:53:12

Results show highly significant dose dependent response Results from a multinational phase II study presented today at the International Liver CongressTM 2010 have shown that treatment with the caspase inhibitor GS-9450 can reduce markers of liver damage in patients with non-alcoholic steatohepatitis (NASH "“ the most serious form of non-alcoholic liver disease) as demonstrated by reduced levels of alanine (ALT) and aspartate aminotransferases (AST), hepatic enzymes that indicate cell...

2010-04-12 09:15:27

Children with more body fat and less endurance than their fitter, leaner counterparts have stiffer arteries at a young age, Medical College of Georgia researchers said. Stiff arteries are a hallmark of atherosclerosis, a typically adult condition in which blood vessels become clogged. "When children at such a young age start getting diseases only adults used to get, it's like the sky is falling," said Dr. Catherine L. Davis, clinical health psychologist in MCG's Georgia Prevention Institute...

2010-01-27 10:55:36

NAFLD and NASH patients at greater risk of death than the general population Researchers from the Karolinska Institute determined that patients with nonalcoholic fatty liver disease (NAFLD) have a higher overall mortality rate compared with the general population. Details of this study are available in the February issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases. While NAFLD is the most common cause of elevated...

2010-01-27 10:51:34

Sonic detection of liver stiffness emerges as a useful screening and prognostic test Researchers from France and Hong Kong determined that transient elastography (TE), a noninvasive, ultrasonic imaging modality, can be accurately performed in the majority of patients with nonalcoholic fatty liver disease (NAFLD) to exclude advanced fibrosis. Full findings of this study, funded by the Chinese University of Hong Kong, appear in the February issue of Hepatology, a journal published by...

2009-11-25 14:23:09

Findings suggest patients with nonalcoholic liver disease are candidates for transplants, but are at increased risk for metabolic syndrome complications Researchers at the University of Miami School of Medicine compared the outcomes of cirrhotic patients who underwent liver transplants for nonalcoholic steatohepatitis (NASH) versus alcoholic liver disease (ETOH) and found no statistically significant differences in post-transplant survival rates between the NASH and ETOH groups. Study...

2009-11-24 16:25:45

Impaired oxidation in liver associated with progression to NASH A recent metobolomics study by researchers from Virginia Commonwealth University Medical Center in Richmond found that impaired peroxisomal oxidation of polyunsaturated fatty acids (PUFA) is associated with the progression of nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH). The study also found significantly higher plasma monounsaturated fatty acids in the blood of patients with NAFL and NASH. Full findings...

2009-10-23 13:38:40

Nonalcoholic fatty liver disease (NAFLD) is often caused by abdominal obesity, which is also one of the main causes of insulin resistance and metabolic syndrome. The latter, in turn, is an important cardiovascular risk factor, and has been found to be associated with the presence of carotid atherosclerotic lesions. It is therefore understandable that an association may exist between NAFLD and carotid lesions. Although the association between NAFLD and carotid lesions is plausible and...

2009-10-12 05:30:00

NOVATO, Calif., Oct. 12 /PRNewswire-FirstCall/ -- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq: RPTPD), announced positive findings from the completed treatment phase of its open-label Phase 2a clinical trial of delayed-release cysteamine bitartrate ("DR Cysteamine") in adolescent patients with non-alcoholic steatohepatitis ("NASH"), a progressive form of liver disease believed to affect 2% to 5% of the U.S. population. At the completion of the initial six-month...

2009-10-01 21:00:00

NEW YORK, Oct. 1 /PRNewswire/ -- Intercept Pharmaceuticals, Inc., has announced that its first-in-class farnesoid X receptor (FXR) agonist INT-747 has met the primary endpoint of improved insulin sensitization in a 6 week double blind, placebo controlled trial in type 2 diabetic patients with nonalcoholic fatty liver disease (NAFLD). By employing a euglycemic insulin clamp procedure, the study demonstrated that a single oral daily dose of INT-747 statistically significantly improved...

2009-09-30 09:58:53

Researchers studying a large sample of adolescent American boys have found an association between metabolic syndrome, which is a complication of obesity, and elevated liver enzymes that mark potentially serious liver disease. The link between metabolic syndrome and the suspected liver disease did not appear in adolescent girls, said study leader Rose C. Graham, M.D., a pediatric gastroenterologist at The Children's Hospital of Philadelphia. There were ethnic differences among the boys as...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.